sur BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Completes IMPD for Multiple Sclerosis Drug Program
BioNxt Solutions Inc., a bioscience firm focusing on innovative drug delivery systems, announces the completion of the Investigational Medicinal Product Dossier (IMPD) for its BNT23001 cladribine oral dissolvable film (ODF). This marks a significant regulatory advance in its development program for treating relapsing multiple sclerosis (MS).
The IMPD consolidates comprehensive pharmaceutical, manufacturing, analytic, non-clinical, and clinical documentation necessary for regulatory review. It is undergoing final technical checks before submission as part of BioNxt's Clinical Trial Application in Europe.
Key achievements include completion of GMP manufacturing and successful preclinical evaluations. The planned clinical trial will assess bioequivalence to the current reference product, Mavenclad®, comparing efficiency, safety, and tolerability in healthy volunteers.
BioNxt's oral film platform aims to simplify drug delivery for patients with swallowing difficulties, offering a patient-centered, needle-free alternative.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioNxt Solutions Inc.